Table 1. Descriptive characteristics of study participants.
| Characteristics | All patients (N = 492) | Age 65–74 years (N = 278) | Age ≥ 75 (N = 214) | PValue |
|---|---|---|---|---|
| Age, years, median (IQR) | 73 (68–78) | 69 (67–71) | 79 (77–83) | <0.001 |
| Gender-male, n (%) | 216 (43.9) | 128 (46) | 88 (41.1) | 0.318 |
| BMI, kg/m2, median (IQR) | 23.565 (21.33–26.015) | 23.81 (21.76–26.55) | 23.155 (21.08–25.4) | 0.004 |
| CRE, mg/dL, median (IQR) | 0.92 (0.68–1.17) | 0.84 (0.66–1.12) | 0.97 (0.8–1.26) | <0.001 |
| eGFR, mL/min/1.73 m2, median (IQR) | 72.915 (54.78–89.98) | 78.79 (60.79–93.97) | 63.535 (47.08–84.22) | <0.001 |
| ALT, U/L, median (IQR) | 47.5 (29.5–81) | 57 (30–91) | 42.5 (29–66) | 0.002 |
| INR, median (IQR) | 0.97 (0.92–1.03) | 0.97 (0.92–1.03) | 0.97 (0.91–1.04) | 0.794 |
| BIL, mg/dL, median (IQR) | 0.74 (0.58–1.01) | 0.8 (0.6–1.04) | 0.7 (0.56–0.97) | 0.019 |
| ALB, g/dL, median (IQR) | 3.8 (3.5–4.1) | 3.9 (3.6–4.2) | 3.7 (3.5–4) | <0.001 |
| HB, g/dL, median (IQR) | 13 (11.5–14.2) | 13.4 (12.1–14.4) | 12.55 (11.2–13.6) | <0.001 |
| FIB-4, median (IQR) | 3.885 (2.655–6.025) | 3.51 (2.38–5.72) | 4.355 (3.31–6.28) | <0.001 |
| Cirrhosis, n (%) | 224 (45.5) | 119 (42.8) | 105 (49.1) | 0.197 |
| Hepatitis B, n (%) | 27 (5.5) | 15 (5.4) | 12 (5.6) | 1.000 |
| Hepatitis B DNA, IU/mL, median (IQR)a | 147.5 (61–208) | 112 (50–143) | 193 (152–208) | 0.175 |
| Comorbidity, n (%) | ||||
| CHD | 1 (0.2) | 1 (0.4) | 0 | 1.000 |
| HIV | 6 (1.2) | 5 (1.8) | 1 (0.5) | 0.240 |
| DM | 93 (18.9) | 48 (17.3) | 45 (21) | 0.347 |
| HTN | 151 (30.7) | 77 (27.7) | 74 (34.6) | 0.123 |
| CVA | 13 (2.6) | 5 (1.8) | 8 (3.7) | 0.295 |
| Any Cancer | 73 (14.8) | 43 (15.5) | 30 (14) | 0.749 |
| Liver Cancer | 39 (7.9) | 22 (7.9) | 17 (7.9) | 1.000 |
| HCV RNA, log10 IU/mL, median (IQR) | 5.77 (4.81–6.27) | 5.8 (4.82–6.28) | 5.74 (4.79–6.26) | 0.649 |
| HCV genotype, n (%) | 0.038 | |||
| Type 1b | 356 (72.4) | 188 (67.6) | 168 (78.5) | |
| Type 2c | 125 (25.4) | 81 (29.1) | 44 (20.6) | |
| Type 4 | 3 (0.6) | 3 (1.1) | 0 | |
| Type 6 | 5 (1) | 3 (1.1) | 2 (0.9) | |
| Mix Typed | 3 (0.6) | 3 (1.1) | 0 | |
| Treatment week, n (%) | 0.411 | |||
| 8 weeks | 64 (13) | 41 (14.7) | 23 (10.7) | |
| 12 weeks | 395 (80.3) | 218 (78.4) | 177 (82.7) | |
| 24 weeks | 33 (6.7) | 19 (6.8) | 14 (6.5) | |
| DAA, n (%) | ||||
| Sofosbuvir/ledipasvir | 224 (45.5) | 107 (38.5) | 117 (54.7) | <0.001 |
| Glecaprevir/pibrentasvir | 90 (18.3) | 56 (20.1) | 34 (15.9) | 0.274 |
| Ombitasvir/paritaprevir/ritonavir/dasabuvir | 74 (15) | 54 (19.4) | 20 (9.3) | 0.003 |
| Otherse | 104(21.1) | 61(21.9) | 43(20.1) | 0.699 |
| Prior interferon therapy, n (%) | 0.022 | |||
| Interferon failure | 72 (14.6) | 51 (18.3) | 21 (9.8) | |
| Interferon naive | 411 (83.5) | 221 (79.5) | 190 (88.8) | |
| Interferon interruption | 9 (1.8) | 6 (2.2) | 3 (1.4) | |
| Child–Pugh Classification for cirrhotic patients, n/N(%) | 0.726 | |||
| A | 216/224 (96.4) | 114/119 (95.8) | 102/105 (97.1) | |
| B | 8/224 (3.6) | 5/119 (4.2) | 3/105(2.9) | |
| Ascites, n (%) | 0.461 | |||
| None | 476 (96.7) | 268 (96.4) | 208 (97.2) | |
| Mild | 14 (2.8) | 8 (2.9) | 6 (2.8) | |
| Moderate | 2 (0.4) | 2 (0.7) | 0 |
Notes.
- BMI
- body mass index
- ALT
- alanine aminotransferase
- BIL
- bilirubin
- ALB
- albumin
- CRE
- Creatinine
- INR
- international normalized ratio
- HB
- haemoglobin
- FIB-4
- Fibrosis-4
- CHD
- coronary heart disease
- HIV
- Human immunodeficiency virus
- DM
- diabetes mellitus
- HTN
- hypertension
- CVA
- cerebrovascular accident
- HCV
- hepatitis C virus
- DAA
- direct antiviral agent
- eGFR
- estimated Glomerular filtration rate
a
HBV DNA data was available for only 10 patients
b
HCV genotype 1 including 1, 1a, 1b
c
HCV genotype 2 including 2, 2a, 2b
d
Mix type including 1or 6, 3, or 4
e
Other DAA regimen, including Daclatasvir/asunaprevir, Sofosbuvir/ribavirin, Sofosbuvir/daclatasvir, Elbasvir/grazoprevir, Sofosbuvir/velpatasvir